Cargando…
Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS
OBJECTIVE: The study was designed to test the efficacy of ATX-MS-1467 in a relevant preclinical model and to assess its safety for the treatment of patients with secondary progressive multiple sclerosis (SPMS). METHODS: ATX-MS-1467 was tested for its ability to suppress experimental autoimmune encep...
Autores principales: | Streeter, Heather B., Rigden, Rachel, Martin, Keith F., Scolding, Neil J., Wraith, David C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360798/ https://www.ncbi.nlm.nih.gov/pubmed/25798453 http://dx.doi.org/10.1212/NXI.0000000000000093 |
Ejemplares similares
-
ATX-MS-1467 Induces Long-Term Tolerance to Myelin Basic Protein in (DR2 × Ob1)F1 Mice by Induction of IL-10-Secreting iTregs
por: De Souza, Adriano Luís Soares, et al.
Publicado: (2018) -
Manipulating antigen presentation for antigen-specific immunotherapy of autoimmune diseases
por: Streeter, Heather B, et al.
Publicado: (2021) -
A New Enzyme Immunoassay for the Quantitative Determination of Classical Autotaxins (ATXα, ATXβ, and ATXγ) and Novel Autotaxins (ATXδ and ATXε)
por: Tokuhara, Yasunori, et al.
Publicado: (2015) -
1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia
por: Albin, Owen, et al.
Publicado: (2018) -
1467. Breakthrough Omicron Infections in Booster Vaccinated Healthcare Workers
por: Lee, Jeongjae, et al.
Publicado: (2022)